Citigroup Inc Kempharm, Inc Transaction History

Citigroup Inc

$190 Billion
Q1 2025

A detailed history of Citigroup Inc transactions in Kempharm, Inc stock. As of the latest transaction made, Citigroup Inc holds 44,121 shares of KMPH stock, worth $217,957. This represents 0.0% of its overall portfolio holdings.

Number of Shares

44,121

Previous 51,284 13.97%

Holding current value

$217,957

Previous $253,000 14.23%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	SELL	N/A	-7,163 Reduced 13.97%	44,121 $217,000
Q4 2024 Feb 12, 2025	BUY	N/A	20,753 Added 67.97%	51,284 $253,000
Q3 2024 Nov 12, 2024	BUY	N/A	21,199 Added 227.16%	30,531 $150,000
Q2 2024 Aug 12, 2024	BUY	N/A	2,279 Added 32.31%	9,332 $46,000
Q1 2024 May 10, 2024	BUY	N/A	1,675 Added 31.15%	7,053 $34,000
Q4 2023 Feb 09, 2024	BUY	N/A	5,360 Added 29777.78%	5,378 $26,000
Q3 2023 Nov 09, 2023	SELL	N/A	-10,314 Reduced 99.83%	18 $0
Q2 2023 Aug 10, 2023	SELL	$4.94 - $6.29 $237,930 - $302,951	-48,164 Reduced 82.34%	10,332 $51,000
Q1 2023 May 11, 2023	SELL	$4.13 - $6.27 $54,722 - $83,077	-13,250 Reduced 18.47%	58,496 $321,000
Q4 2022 Feb 09, 2023	BUY	$4.12 - $5.62 $278,994 - $380,569	67,717 Added 1680.74%	71,746 $329,000
Q3 2022 Nov 10, 2022	BUY	$4.5 - $6.85 $14,337 - $21,824	3,186 Added 377.94%	4,029 $25,000
Q2 2022 Aug 10, 2022	SELL	$4.02 - $5.21 $5,197 - $6,736	-1,293 Reduced 60.53%	843 $4,000
Q1 2022 May 12, 2022	SELL	$5.0 - $9.26 $33,495 - $62,032	-6,699 Reduced 75.82%	2,136 $11,000
Q4 2021 Feb 10, 2022	BUY	$7.6 - $10.26 $42,392 - $57,230	5,578 Added 171.26%	8,835 $77,000
Q3 2021 Nov 10, 2021	BUY	$8.72 - $13.31 $28,401 - $43,350	3,257 New	3,257 $30,000

Others Institutions Holding KMPH

# of Institutions

121

Shares Held

31.8M

Call Options Held

186K

Put Options Held

597K

View Full List

About KEMPHARM, INC

Ticker KMPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,493,600
Market Cap $170M
Description
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds t...

More about KMPH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account